Alveus Therapeutics Announces FDA Clearance of IND and First Patient Dosed in Phase 1b Trial of ALV-100 for Obesity

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ALV-100, the company’s lead investigational therapy for chronic weight management, enabling initiation of a Phase 1b clinical study. The first patient was dosed last week.

ALV-100 is a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein designed to address long-term weight management and tolerability in adults with obesity.

The Phase 1b study is a randomized, double-blind, placebo-controlled, dose-escalation trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ALV-100 in adults with overweight or obesity, with or without type 2 diabetes. Approximately 180 patients will be enrolled across multiple U.S. clinical sites.

“Following the successful close of our Series A financing earlier this month, we moved quickly to advance ALV-100 into the clinic in the United States,” said Raj Kannan, Chief Executive Officer of Alveus. “ALV-100 was designed not only to drive robust weight loss but also to support long-term weight maintenance with a simpler treatment approach. This IND clearance and first patient dosing are critical steps toward building a robust Phase 3 program.”

ALV-100 is being developed to support long-term weight management with a focus on convenience and tolerability. Alveus’ strategy is focused on evaluating dosing regimens that better match real-world patient needs over time.

“We believe combining GIPR antagonism with GLP-1 receptor agonism can support long-term weight management with a better treatment experience,” said Jacob Jeppesen, PhD, Chief Scientific Officer and Head of R&D at Alveus. “This Phase 1b study is the first of several planned milestones as we move toward Phase 3 readiness in the second half of 2027.”

About Alveus Therapeutics

Alveus is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden.

Alveus acquired global development and commercialization rights outside of greater China to ALV-100 from Gmax Biopharm International Limited in 2024.

Alveus is headquartered in Philadelphia, PA, with research and development operations based in Copenhagen, Denmark.

For more information, visit www.alveustx.com

Investor & Media Contacts
Alveus Therapeutics

Media
Sasha Damouni Ellis, Damouni Group LLC
sasha@damounigroup.com

Investors
Victoria Igumnova, Meru Advisors LLC
vigumnova@meruadvisors.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.